Duloxetine treatment of Premenstrual Dysphoric Disorder: Case reports

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 579-580

  Ramos, M G ^a   Hara, C ^a   Rocha, F L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DULOXETINE; IMIPRAMINE; LITHIUM; NORTRIPTYLINE; REBOXETINE; TRANYLCYPROMINE; VENLAFAXINE;

ADULT; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR DEPRESSION; MONOTHERAPY; PATHOGENESIS; PREMENSTRUAL DYSPHORIC DISORDER; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 38749090954     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.09.006     Document Type: Letter

References (13)

1. Brannan S.K., Mallinckrodt C.H., Brown E.B., Wohlreich M.M., Watkin J.G., and Schatzberg A.F. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39 (2005) 43-53
2. Cohen L.S., Soares C.N., Lyster A., Cassano P., Brandes M., and Leblanc G.A. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 24 (2004) 1-4
3. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., and Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63 (2002) 308-315
4. Dimmock P.W., Wyatt K.M., Jones P.W., and O'Brien P.M.S. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review. Lancet 356 (2000) 1131-1136
5. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 14 (1999) 527-533
6. Freeman E.W. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 18 (2004) 453-468
7. Hambrecht U., Bornstein J., Pearlstein T., and Kahn L.S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28 (2003) 1-23
8. Parry B.L. The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs 15 (2001) 277-285
9. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?. Drugs 62 (2002) 1869-1885
10. Steiner M., and Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15 Suppl 3 (2000) 5-17
11. Steiner M., and Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 61 Suppl 12 (2000) 17-21
12. Sundblad C., Modigh K., Andersch B., and Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 85 (1992) 39-47
13. Yonkers K.A. Management strategies for PMS/PMDD. J Fam Pract (2004) S15-S20 [Suppl]